Evidence map›Paper›PMID 25847999›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2015

Edaravone alleviates Alzheimer's disease-type pathologies and cognitive deficits.

Shu-Sheng Jiao, Xiu-Qing Yao, Yu-Hui Liu, Qing-Hua Wang, Fan Zeng, Jian-Jun Lu, Jia Liu, Chi Zhu, Lin-Lin Shen, Cheng-Hui Liu and 17 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 1 pooled it
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 1 synthesis or guideline pooled it, 175 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Study of the multitarget mechanism ofPharmaceutical biology · 2024
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 4 institutions in 2 countries.

Shu-Sheng JiaoDepartment of Neurology, Daping Hospital, Third Military Medical University, Chongqing 400042, China;
Xiu-Qing YaoDepartment of Neurology, Daping Hospital, Third Military Medical University, Chongqing 400042, China;
Yu-Hui LiuDepartment of Neurology, Daping Hospital, Third Military Medical University, Chongqing 400042, China;
Qing-Hua WangDepartment of Neurology, Daping Hospital, Third Military Medical University, Chongqing 400042, China;
Fan ZengDepartment of Neurology, Daping Hospital, Third Military Medical University, Chongqing 400042, China;
Jian-Jun LuSchool of Pharmacy and Medical Sciences and Sansom Institute, Division of Health Sciences, University of South Australia, Adelaide, SA 5000, Australia;
Jia LiuSchool of Pharmacy and Medical Sciences and Sansom Institute, Division of Health Sciences, University of South Australia, Adelaide, SA 5000, Australia;
Chi ZhuDepartment of Neurology, Daping Hospital, Third Military Medical University, Chongqing 400042, China;
Lin-Lin ShenDepartment of Neurology, Daping Hospital, Third Military Medical University, Chongqing 400042, China;
Cheng-Hui LiuDepartment of Neurology, Daping Hospital, Third Military Medical University, Chongqing 400042, China;
Ye-Ran WangDepartment of Neurology, Daping Hospital, Third Military Medical University, Chongqing 400042, China;
Gui-Hua ZengDepartment of Neurology, Daping Hospital, Third Military Medical University, Chongqing 400042, China;
Ankit ParikhSchool of Pharmacy and Medical Sciences and Sansom Institute, Division of Health Sciences, University of South Australia, Adelaide, SA 5000, Australia;
Jia ChenDepartment of Neurology, Daping Hospital, Third Military Medical University, Chongqing 400042, China;
Chun-Rong LiangDepartment of Neurology, Daping Hospital, Third Military Medical University, Chongqing 400042, China;
Yang XiangDepartment of Neurology, Daping Hospital, Third Military Medical University, Chongqing 400042, China;
Xian-Le BuDepartment of Neurology, Daping Hospital, Third Military Medical University, Chongqing 400042, China;
Juan DengDepartment of Neurology, Daping Hospital, Third Military Medical University, Chongqing 400042, China;
Jing LiDepartment of Neurology, Daping Hospital, Third Military Medical University, Chongqing 400042, China;
Juan XuDepartment of Neurology, Daping Hospital, Third Military Medical University, Chongqing 400042, China;
Yue-Qin ZengInstitute of Molecular and Clinical Medicine, Kunming Medical University, Kunming 650031, China;
Xiang XuResearch Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing 400042, China; and.
Hai-Wei XuSouthwest Eye Hospital, Southwest Hospital, Third Military Medical University, Chongqing 400038, China.
Jin-Hua ZhongSchool of Pharmacy and Medical Sciences and Sansom Institute, Division of Health Sciences, University of South Australia, Adelaide, SA 5000, Australia;
Hua-Dong ZhouDepartment of Neurology, Daping Hospital, Third Military Medical University, Chongqing 400042, China;
Xin-Fu ZhouSchool of Pharmacy and Medical Sciences and Sansom Institute, Division of Health Sciences, University of South Australia, Adelaide, SA 5000, Australia; Institute of Molecular and Clinical Medicine, Kunming Medical University, Kunming 650031, China; xin-fu.zhou@unisa.edu.au yanjiang_wang@tmmu.edu.cn.
Yan-Jiang WangDepartment of Neurology, Daping Hospital, Third Military Medical University, Chongqing 400042, China; xin-fu.zhou@unisa.edu.au yanjiang_wang@tmmu.edu.cn.
Army Medical University · CNDaping Hospital · CNUniversity of South Australia · AUSouthwest Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is one of most devastating diseases affecting elderly people. Amyloid-β (Aβ) accumulation and the downstream pathological events such as oxidative stress play critical roles in pathogenesis of AD. Lessons from failures of current clinical trials suggest that targeting multiple key pathways of the AD pathogenesis is necessary to halt the disease progression. Here we show that Edaravone, a free radical scavenger that is marketed for acute ischemic stroke, has a potent capacity of inhibiting Aβ aggregation and attenuating Aβ-induced oxidation in vitro. When given before or after the onset of Aβ deposition via i.p. injection, Edaravone substantially reduces Aβ deposition, alleviates oxidative stress, attenuates the downstream pathologies including Tau hyperphosphorylation, glial activation, neuroinflammation, neuronal loss, synaptic dysfunction, and rescues the behavioral deficits of APPswe/PS1 mice. Oral administration of Edaravone also ameliorates the AD-like pathologies and memory deficits of the mice. These findings suggest that Edaravone holds a promise as a therapeutic agent for AD by targeting multiple key pathways of the disease pathogenesis.

Indexed as

Administration, OralAlzheimer DiseaseAmyloidAmyloid beta-PeptidesAnimalsAntipyrineBehavior, AnimalBrainCell LineCognition DisordersDendritesEdaravoneHumansInflammationMice, TransgenicNeurotoxinsAmyloidAmyloid beta-PeptidesAntipyrineEdaravoneNeurotoxinsPresenilin-1tau ProteinsAlzheimer’s diseaseamyloid-βBACE1Edaravoneoxidative stress

Identifiers

PMID25847999
PMCPMC4413288
OpenAlexW2171818152

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.